Assessing Functional Impairments in CIPN Patients
Official title: Assessing Functional Impairments in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Run by Paracelsus Medical University · NCT07315334 · Data updated 2026-11-12
This study tests how CIPN affects daily function by using functional tests alongside patient self-reports to see how well the tests reflect everyday difficulties.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Paracelsus Medical University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Salzburg) |
| Status | Recruiting |
| Started | March 15, 2026 |
| Main results expected | March 31, 2027 |
| Study ends | March 31, 2027 |
| Registry record updated | August 19, 2026 |
| Trial ID | NCT07315334 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with CIPN grade 2 or higher who can stand, walk, and complete questionnaires.
✕Probably not a fit
Patients with pre-existing non-CIPN neuropathies or conditions severely limiting mobility may not see benefit from these assessments.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This cross-sectional study examines functional impairments in adults with chemotherapy-induced peripheral neuropathy (CIPN) and compares objective functional assessments with patient-reported outcomes. Participants complete questionnaires and undergo physical exams to measure daily activity limitations, gait and balance, and fine motor function. The goal is to better understand how objective tests correlate with patients’ subjective experiences and to identify which assessments best reflect real-world impact of CIPN.
Why it matters
Potential benefit: If successful, the study could improve how CIPN-related disability is measured and monitored in patients receiving chemotherapy.
How similar studies have gone: Previous work suggests objective functional measures can complement patient-reported symptoms in CIPN, but the added value of specific tests like gait and 9-hole peg task needs confirmation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Male and female patients with CIPN grade ≥ 2, according to Common Terminology Criteria for Adverse Events for peripheral sensory or motor neuropathy (CTCAE) version 5 \- Age ≥ 18 \- Ongoing or completed neuropathy-inducing chemotherapy \- Ability to stand and walk \- Ability to fill out a questionnaire Inclusion criteria for healthy controls \- Male and female adults (age ≥ 18) \- Ability to stand and walk \- Ability to fill out a questionnaire Exclusion Criteria: * Pre-existing clinically manifest peripheral neuropathy prior to start of chemotherapy (e.g. caused by radiation or malignant plexopathy, lumbar or cervical radiculopathy, carpal tunnel syndrome, B12 deficiency, AIDS, monoclonal gammopathy, diabetes, heavy metal poisoning amyloidosis, syphilis, hyperthyroidism or hypothyroidism, inherited neuropathy, etc.) Acute or chronic injuries/ diseases of the musculoskeletal system affecting functional tests \- Acute or chronic cardiovascular diseases affecting functional tests \- Neurological disease affecting functional tests (for healthy controls) \- Neurological disease other than CIPN affecting functional tests (for CIPN patients)
Where it's running
-
Institute of Physical Medicine and Rehabilitation, University Hospital Salzburg
Salzburg, Austria Recruiting
Study contacts
- Study coordinator: Florian Rieder, PhD
- Email: f.rieder@salk.at
- Phone: 00435725553182
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cryotherapy during weekly paclitaxel to reduce chemotherapy-induced numbness and tingling
This study tests whether applying cryotherapy to hands and feet during weekly paclitaxel helps prevent CIPN in women with breast cancer.
-
Electroacupuncture and Exercise for Chemotherapy-Induced Peripheral Neuropathy
This study tests whether adding a structured exercise program to electroacupuncture helps cancer survivors with CIPN more than electroacupuncture alone.
-
Virtual exercise program to help with chemotherapy-induced nerve symptoms
This trial tests whether a remote, personalized exercise program (EX-CIPN) can reduce CIPN symptoms and related disability in cancer survivors who have persistent neuropathy after chemotherapy, compared with usual care.
-
Acupuncture and compression to prevent chemotherapy-induced nerve damage in breast cancer
This trial will test whether wearing compression garments and/or receiving acupuncture during taxane chemotherapy can prevent chemotherapy-induced peripheral neuropathy in adults with early-stage breast cancer.
-
PEA and Scutellaria combined with exercise for chemotherapy-related nerve pain
This trial will see if taking PEA and Scutellaria together with therapeutic exercise helps adults who have nerve pain after chemotherapy.
-
Closed-loop spinal cord stimulation for painful chemotherapy-induced peripheral neuropathy
This observational project will try closed-loop spinal cord stimulation to reduce neuropathic pain in adults who developed peripheral neuropathy after chemotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.